AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05751798
Drug: OSE-279 100mg
RxNorm normalized name: OSE-2101
DrugBank: OSE-2101 (DB17122)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human IgG4 mAb against PD-1
Trial: NCT05751798
Drug: OSE-279 300mg
RxNorm normalized name: OSE-2101
DrugBank: OSE-2101 (DB17122)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human IgG4 mAb against PD-1
Trial: NCT05751798
Drug: OSE-279 500mg
RxNorm normalized name: OSE-2101
DrugBank: OSE-2101 (DB17122)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human IgG4 mAb against PD-1
Trial: NCT05926856
Drug: Indocyanine green
RxNorm normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Indocyanine Green 25mg kit for injection
Trial: NCT04481945
Drug: bioceramic sealer
RxNorm normalized name: Iocetamic acid
DrugBank: Iocetamic acid (DB09403)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: pre-mixed bioceramic obturation material. It is dispensed using a syringe in cases of root canal obturation and with either a syringe or as a putty when doing root repair and retrograde fillings.
Trial: NCT04828031
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient with inflammatory bowel disease who have low vitamin D (25(OH)D less than or equal to 25 ng/mL) will take Vitamin D 50,000 IU by mouth every week for 12 weeks. Patients will fill out questionnaires to document disease activity score (HBI or Mayo score and sIBDQ) and have blood and stool samples collected before (Week 0), during (Week 8) and after (Week 12) vitamin D intervention.
Trial: NCT04954521
Drug: Anlotinib
RxNorm normalized name: Anlotinib
DrugBank: Anlotinib (DB11885)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is an observational study
Trial: NCT05525351
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The investigators assess the depth of anesthesia based on bispectral index (BIS) or Patient State Index (PSI) after routine drug regimen is given. BIS is maintained between 40 and 60 and or PSI between 25 and 50. The drug doses are given as a part of routine anesthesia practice and is identical regardless of study participation. Propofol is given via target control pump with typical target effect-site propofol concentration 1-5 ug/mL according to patient condition, BIS or PSI value and DSA. The timing and doses are recorded for backend analysis. At the conclusion of the surgery or examination, the patient is observed in the surgery or examination room until return of consciousness before sending them to the recovery unit.
Trial: NCT05525351
Drug: Alfentanil
RxNorm normalized name: Alfentanil
DrugBank: Alfentanil (DB00802)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The investigators assess the depth of anesthesia based on bispectral index (BIS) or Patient State Index (PSI) after routine drug regimen is given. BIS is maintained between 40 and 60 and or PSI between 25 and 50. The drug doses are given as a part of routine anesthesia practice and is identical regardless of study participation. Typical alfentanil ranged from 0\~1000mcg according to patient condition, BIS or PSI value and DSA. The timing and doses are recorded for backend analysis. At the conclusion of the surgery or examination, the patient is observed in the surgery or examination room until return of consciousness before sending them to the recovery unit.
Trial: NCT05525351
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The investigators assess the depth of anesthesia based on bispectral index (BIS) or Patient State Index (PSI) after routine drug regimen is given. BIS is maintained between 40 and 60 and or PSI between 25 and 50. The drug doses are given as a part of routine anesthesia practice and is identical regardless of study participation. Typical Dexmedetomidine ranged from 0.5-1 ug/kg/hr according to patient condition, BIS or PSI value and DSA. The timing and doses are recorded for backend analysis. At the conclusion of the surgery or examination, the patient is observed in the surgery or examination room until return of consciousness before sending them to the recovery unit.
Trial: NCT04839744
Drug: TG103 produced by the modified manufacturing process
RxNorm normalized name: Glycyrrhiza Glabra Processed Root
DrugBank: Glycyrrhiza glabra (DB14312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: TG103 (a modified manufacturing process), 15mg, SC
Trial: NCT04839744
Drug: TG103 produced by the original manufacturing process
RxNorm normalized name: capsaicin
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Drug: TG103 (the original manufacturing process), 15mg, SC
Trial: NCT03462810
Drug: cabotegravir, CAB
DrugBank: Cabotegravir (DB11751)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: open label investigational product
Trial: NCT04864743
Drug: ADVATE
RxNorm normalized name: Advate
DrugBank: Antihemophilic factor, human recombinant (DB00025)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a single dose.
Trial: NCT05083663
Drug: Hyaluronidase
RxNorm normalized name: Hyaluronidase
DrugBank: Hyaluronidase (ovine) (DB00070)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: using hyaluronidase as an additive to bupivacaine
Trial: NCT05208333
Drug: Albenza 200Mg Tablet
RxNorm normalized name: Albenza 200mg Tablet
DrugBank: Albendazole (DB00518)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Distributing albedazol (Zentel) 200mg at school to parents or guardians, dose 15mg/kg divided into 2 times/day, instructions to take the medicine in full dose, at the right time after meals, for 5 days.~Limiting reinfection: Advice on preventing reinfection
Trial: NCT04927884
Drug: Sacituzumab Govitecan-Hziy
RxNorm normalized name: sacituzumab govitecan-hziy
DrugBank: Sacituzumab govitecan (DB12893)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Phase 1b:~Dose level 1: Sacituzumab govitecan-hziy (7.5 mg/kg IV) Dose level 2: Sacituzumab govitecan-hziy (10 mg/kg IV) Dose level -1 (if needed): Sacituzumab govitecan-hziy (5.0 mg/kg IV)~Phase 2: Dose based on Phase 1b Recommended Phase 2 Dose (IV)~Frequency: administered on Days 1 and 8 of each cycle (every 3 weeks)
Trial: NCT04858308
Drug: Control
RxNorm normalized name: Control
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Active control
Trial: NCT05597995
Drug: Sodium Tetradecyl Sulfate
RxNorm normalized name: Sodium Tetradecyl Sulfate
DrugBank: Sodium tetradecyl sulfate (DB00464)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: subjects epidermoid cysts will be treated with 1.5% sodium tetradecyl sulfate foam
Trial: NCT05491343
Drug: MedroxyPROGESTERone Injection [Depo-Provera]
RxNorm normalized name: medroxyprogesterone Injection [Depo-Provera]
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The drug-induced endometrial changes would likely to prevent the shedding of endometrium, in turn preventing the exposure of AVM.
Trial: NCT05474183
Drug: Ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: drug
Trial: NCT00002223
Drug: Indinavir sulfate
RxNorm normalized name: Indinavir Sulfate
DrugBank: Indinavir (DB00224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002223
Drug: Ritonavir
RxNorm normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT06551896
Drug: Pemigatinib
RxNorm normalized name: Pemigatinib
DrugBank: Pemigatinib (DB15102)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pemigatinib and immune checkpoint inhibitors
Trial: NCT06343116
Drug: Nimotuzumab injection
RxNorm normalized name: inotuzumab ozogamicin Injection
DrugBank: Nimotuzumab (DB06192)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nimotuzumab will be administered weekly (dose of nimotuzumab depends on part A) until disease progression, unacceptable toxicity, withdrawal of consent or death due to any cause.
Trial: NCT05016518
Drug: Arm I (Propofol group)
RxNorm normalized name: IOBENGUANE I 123
DrugBank: Iobenguane (DB06704)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propfol group will be started and maintained total intravenous anesthesia with propofol and remifentanil .
Trial: NCT05016518
Drug: Arm II (Remimazolam group)
RxNorm normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Remimazolam group will be started and maintained total intravenous anesthesia with remimazolam and remifentanil.
Trial: NCT06531993
Drug: Pectin
RxNorm normalized name: Pectin
DrugBank: Pectin (DB11158)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Using pectin as tablets 600 mg per day for 6 months
Trial: NCT05981742
Drug: Metformin Hydrochloride 500 MG
RxNorm normalized name: metformin hydrochloride 500 MG
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Brand name: (Glucophage) Tablets per oral / Twice daily / 90 days duration
Trial: NCT05981742
Drug: Cabergoline 0.5 MG
RxNorm normalized name: cabergoline 0.5 MG
DrugBank: Cabergoline (DB00248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Brand name: (Pergoline) Tablets per oral / single dose per week / 90 days duration
Trial: NCT05981742
Drug: Metformin Hydrochloride 500 MG + Cabergoline 0.5 MG
DrugBank: Cabergoline (DB00248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metformin Brand name: (Glucophage) Tablets per oral / Twice daily / 90 days duration~Cabergoline Brand name: (Pergoline) Tablets per oral / single dose per week / 90 days duration
Trial: NCT06441318
Drug: Povorcitinib
RxNorm normalized name: Povorcitinib
DrugBank: Povorcitinib (DB18855)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Povorcitinib will be administered at protocol defined dose.
Trial: NCT06441318
Drug: Moxifloxacin
RxNorm normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Moxifloxacin will be administered at protocol defined dose.
Trial: NCT05200273
Drug: AK114
RxNorm normalized name: Alprazolam
DrugBank: Alprazolam (DB00404)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: AK114 administered by subcutaneous injection
Trial: NCT05306847
Drug: Sintilimab
RxNorm normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sintilimab will be given intravenously at a dose of 200mg every 21 days.
Trial: NCT05306847
Drug: Anlotinib
RxNorm normalized name: Anlotinib
DrugBank: Anlotinib (DB11885)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anlotinib will be given at a dose of 12mg once daily on days 1-14 of a 21-day cycle.
Trial: NCT05833126
Drug: Hepatic arterial infusion chemotherapy + Atezolizumab and bevacizumab
RxNorm normalized name: Atezolizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Drug: Oxaliplatin, calcium folinate, 5-FU, Atezolizumab and bevacizumab Procedure: HAIC
Trial: NCT04613518
Drug: BMS-986165
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Specified Dose on Specified Days
Trial: NCT05668897
Drug: GST-HG171
RxNorm normalized name: camphor
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: This study includes single-dose ascending and multiple-dose ascending studies. SAD study contains at least 4 dose groups of 150 mg, 300 mg, 600 mg and 900 mg. MAD study contains 1-3 dose groups which were evaluated in SAD study to be tolerated.
Trial: NCT05664555
Drug: Fluorescein Sodium
RxNorm normalized name: Fluorescein Sodium
DrugBank: Fluorescein (DB00693)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive Fluorescein Sodium 3mL (300mg) or 1mL (100mg) intravenously prior to fluorescein angiography.
Trial: NCT06450223
Drug: Perampanel 12 MG
RxNorm normalized name: perampanel 12 MG
DrugBank: Perampanel (DB08883)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1 tablet of Perampanel Tablets 12 mg
Trial: NCT04732260
Drug: Letermovir
RxNorm normalized name: Letermovir
DrugBank: Letermovir (DB12070)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Each patient will receive 1 tablet of Letermovir (240 mg or 480 mg /day) during 3 days before TOP.~5 women will receive 240 mg. 5 women will receive 480 mg.
Trial: NCT05382104
Drug: Maribavir
RxNorm normalized name: MARIBAVIR
DrugBank: Maribavir (DB06234)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Maribavir single 400 mg tablet under three different food conditions (fasted, low fat/low calorie meal, and high fat/high calorie meal) depending upon the treatment sequence allocation on Day 1 of each treatment period.
Trial: NCT06552624
Drug: Magaldrate
RxNorm normalized name: Magaldrate
DrugBank: Magaldrate (DB08938)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A dose of T drug in one of 2 periods of the study 2 h prior to food intake, 3 times per day
Trial: NCT06552624
Drug: Magaldrate
RxNorm normalized name: Magaldrate
DrugBank: Magaldrate (DB08938)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A dose of R drug in one of 2 periods of the study 2 h prior to food intake, 3 times per day
Trial: NCT06464679
Drug: CD19 CAR NK cells
RxNorm normalized name: CAR.CD19-Redirected T cells
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive Fludarabine (25 mg/m2 per day) and Cyclophosphamide (300mg/m2 per day) on day -5, -4, and -3. Multiple doses of CD19 CAR NK cells will infused using the dose-escalation strategy.
Trial: NCT06307223
Drug: 30% supramolecular salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patients received weekly application of 30% supramolecular salicylic acid for a duration of 8 weeks.
Trial: NCT05907525
Drug: Remimazolam
RxNorm normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: To induce anesthesia, remimazolam is continuously infused in a dose of 6mg/kg/hr with remifentanil (Ce of 1-4ng/ml) by target-controlled infusion (TCI). Maintenance dose of remimazolam is 1mg/kg/hr, up to 2mg/kg/hr, and remifentanil is titrated to maintain the bispectral index (BIS) between 40 and 60 to achieve appropriate anesthetic depth during general anesthesia.~Inspired oxygen fraction (FiO2) 1.0 is used during mask ventilation and tracheal intubation. During two lung ventilation (TLV), tidal volumes (8mL/kg predicted body weight), positive end-expiratory pressure (PEEP) 5cmH2O with FiO2 0.3 is applied. At the start of one lung ventilation(OLV), tidal volumes (5mL/kg predicted body weight), PEEP 5cmH2O with FiO2 0.8 is applied. Intraoperative ventilatory frequency is 12 breaths/min, subsequently adjusted to maintain end tidal CO2(ETCO2) ranged between 35-40mmHg.
Trial: NCT05907525
Drug: 1% propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: To induce anesthesia, 1% propofol 1.5-2.5mg/kg is used with remifentanil (Ce of 1-4ng/ml) by target-controlled infusion (TCI). After patient loses consciousness, anesthesia is maintained through the inhalation of sevoflurane between 1-2 minimum alveolar concentrations (MAC), and remifentanil is titrated to maintain the bispectral index (BIS) between 40 and 60 to achieve appropriate anesthetic depth during general anesthesia.~Inspired oxygen fraction (FiO2) 1.0 is used during mask ventilation and tracheal intubation. During two lung ventilation (TLV), tidal volumes (8mL/kg predicted body weight), positive end-expiratory pressure (PEEP) 5cmH2O with FiO2 0.3 is applied. At the start of one lung ventilation(OLV), tidal volumes (5mL/kg predicted body weight), PEEP 5cmH2O with FiO2 0.8 is applied. Intraoperative ventilatory frequency is 12 breaths/min, subsequently adjusted to maintain end tidal CO2(ETCO2) ranged between 35-40mmHg.
Trial: NCT00000863
Drug: Sitamaquine
RxNorm normalized name: Sitamaquine
DrugBank: Sitamaquine (DB04909)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00002424
Drug: L-756423
RxNorm normalized name: L
DrugBank: L-756423 (DB02009)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00002424
Drug: Indinavir sulfate
RxNorm normalized name: Indinavir Sulfate
DrugBank: Indinavir (DB00224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002424
Drug: Lamivudine
RxNorm normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00002424
Drug: Stavudine
RxNorm normalized name: Stavudine
DrugBank: Stavudine (DB00649)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05724342
Drug: rhTNK-tPA Thrombolysis
RxNorm normalized name: tPA
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: rhTNK-tPA Thrombolysis
Trial: NCT04331288
Drug: PT150
RxNorm normalized name: Mifepristone
DrugBank: Mifepristone (DB00834)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intervention 1 includes PT150 with alcohol consumption
Trial: NCT06409104
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: will receive 1-2 mgkg-1 propofol injection over 30s followed by of propofol a 0.05 to 0.1 mg /kg/min infusion
Trial: NCT05324319
Drug: Ad26COVS1
RxNorm normalized name: Ad26COVS1
DrugBank: Janssen COVID-19 Vaccine (DB15857)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heterologous vaccination
Trial: NCT05324319
Drug: ChAdOx1 SARS2 Vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heterologous vaccination
Trial: NCT05324319
Drug: BNT162B2
RxNorm normalized name: BNT162b2 Omicron (KP.2)
DrugBank: BNT162b2 Omicron (KP.2) (DB19415)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Homologous vaccination
Trial: NCT05324319
Drug: mRNA-1273
RxNorm normalized name: MRNA-1273 SARS-COV-2
DrugBank: Moderna COVID-19 Vaccine (DB15654)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Homologous vaccination
Trial: NCT04449965
Drug: Povidone-iodine
RxNorm normalized name: Povidone-Iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: This will be performed twice daily for two weeks.
Trial: NCT05775601
Drug: 18F-LY3950321
RxNorm normalized name: (18F)-Fluoride
DrugBank: Fluoride ion F-18 (DB09398)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 millicuries (±1 mCi)
Trial: NCT05444582
Drug: Levonorgestrel 52 MG Intrauterine System
RxNorm normalized name: levonorgestrel 52 MG Intrauterine System
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Eligible participants must be 16-35 years old, meet clinic eligibility for IUD placement, and having a LNG 52 mg IUD placed for either:~Emergency Contraception (had unprotected intercourse in the last 5 days) OR Same-day start - \>7 days since the onset of last menstrual period and have no report of unprotected intercourse in the last 5 days.
Trial: NCT05728736
Drug: Lemborexant 25 mg
DrugBank: Lemborexant (DB11951)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lemborexant 25mg will be taken nightly for two consecutive nights.
Trial: NCT06409104
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: will receive dexmedetomidine at a loading dose of 1 μg/kg over 10 min, followed by a 0.2-0.7-μg/kg/h infusion.
Trial: NCT06561633
Drug: Sugammadex administration
DrugBank: Sugammadex (DB06206)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: After surgery was completed while the train-of-four ratio was zero, a steady-state intravenous anesthesia was maintained to keep a BIS value within the range of 40-60 for at least 5 minutes. Patients received sugammadex 2 mg.kg-1 after completed surgery.
Trial: NCT04851132
Drug: Durvalumab
RxNorm normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Durvalumab 1000 mg, intravenously (IV), on Day 1 of radiotherapy, every 3 weeks for up to 18 administrations.
Trial: NCT05427500
Drug: 5 mL of 0.5% preservative-free bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV will be inserted. Patient will be connected to cardiorespiratory monitors. The neck will be cleansed twice. A high frequency (15-6 MHz) linear ultrasound probe will be used to identify the arteries, jugular vein, and other important vasculature. Once a clear path for the needle is identified, the skin is anesthetized. A cutting tip spinal needle is then inserted at the lateral aspect of the field and advanced in-plane under ultrasound visualization. A test injection is injected to verify placement, then 5 mL of 0.5% preservative-free bupivacaine will be injected. Per standard SGB procedure, vitals will be measured post-SGB and participants will remain in the clinic for approximately 15 minutes to monitor for any serious adverse events.
Trial: NCT04864054
Drug: Regorafenib (STIVARGA®, BAY73-4506)
RxNorm normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Regorafenib pretreatment before an ECT204 infusion.
Trial: NCT05052853
Drug: NMDAE
RxNorm normalized name: NMDA
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Use of an NMDA enhancer for the treatment of prodromal schizophrenia .
Trial: NCT05493293
Drug: NBI-921352
RxNorm normalized name: NBI-98782
DrugBank: NBI-98782 (DB16905)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets for oral administration
Trial: NCT04659707
Drug: Hyperpolarized Xe129
RxNorm normalized name: xenon-129, hyperpolarized
DrugBank: Xenon (DB13453)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will inhale up to 4 doses of hyperpolarized Xenon gas in order to image pulmonary function.
Trial: NCT04777760
Drug: one dose of surfactant replacement
RxNorm normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: the preterm infants diagnosed with NRDS and/or NARDS will be administrated with only one dose of surfactant
Trial: NCT06504576
Drug: Cilostazol 50 MG Oral Tablet
RxNorm normalized name: cilostazol 50 MG Oral Tablet
DrugBank: Cilostazol (DB01166)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Two consecutive weeks of Cilostazol (50mg BID) two days after admission
Trial: NCT05101018
Drug: Romosozumab
RxNorm normalized name: ROMOSOZUMAB
DrugBank: Romosozumab (DB11866)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Romosozumab (Amgen Inc., Thousand Oaks, CA) 210mg SQ administered each month
Trial: NCT05101018
Drug: Denosumab
RxNorm normalized name: Denosumab
DrugBank: Denosumab (DB06643)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Denosumab (Amgen Inc., Thousand Oaks, CA) 60 mg SQ administered every six months